🎙️ Voice is AI-generated. Inconsistencies may occur.
COVAX's vaccine supply outlook was cut by over 100 million doses as a devastating COVID-19 surge hits India, the Associated Press reported.
One of COVAX's key suppliers is an Indian manufacturer that has prioritized the needs at home.
Gavi, the Vaccine Alliance, a public health group that manages the U.N.-backed COVAX program, said the move lowered COVAX's estimated dose distribution total to just under 1.9 billion this year, including 1.5 billion promised to 92 poor countries.
So far, it has been able to distribute about 90 million doses, well short of the original goal.
For more reporting from the Associated Press, see below.
The shortfall comes because the Serum Institute of India—a pivotal producer of vaccines for COVAX—has reverted supplies to needy people in India, as its government scrambled to fight a spike in infections.
Recent dose-sharing announcements by rich countries like the United States that have or are nearing excess supply of COVID-19 vaccines are expected to help fill the gap by several hundred million doses, according to a Gavi official.
Uncertainties remain in the new supply forecast, including when large-scale exports of vaccines will resume from the Serum Institute; regulatory processes for candidate vaccines such as one from Novavax, another key potential supplier; and when countries actually donate doses.
The World Health Organization has repeatedly urged wealthy countries to do more to release stockpiles of, or rights to, vaccines to offset unequal access to coronavirus shots. It says the vast majority of vaccinations so far have been in the developed world.
WHO officials insist timing is crucial, with doses needed now to prevent the emergence of worrying new variants like the delta variant, which originally appeared in India and has been blamed for increased transmission of COVID-19 in many countries.
The revised forecast comes as Gavi's board was preparing Thursday to revise the way it operates with nearly 100 middle- and upper-income countries and territories that also take part in COVAX but are paying for access to vaccines through it—so-called "self-financing participants" or SFCs.
Many of those participants, including Britain, Canada, European Union member states, Japan, South Korea and wealthy Gulf states, have lined up other ways of getting vaccines and have not benefited from doses through COVAX. The U.S. funds and supplies COVAX, but isn't a participant.
Instead, the Gavi board plans to focus COVAX's efforts on middle- and upper-middle-income countries—such as Colombia or Argentina—that face challenges in getting vaccines and could still benefit from COVAX.
"The reality is that today, some self-financing participants, especially higher-income economies, do not need to rely on COVAX for vaccines," Gavi said.
Gavi, a public-private partnership, manages the program along with the Coalition for Epidemic Preparedness Innovations, the WHO and UNICEF, the U.N. children's agency that helps deploy doses once they get delivered to recipient countries in the COVAX program.
Newsweek, in partnership with NewsGuard, is dedicated to providing accurate and verifiable vaccine and health information. With NewsGuard's HealthGuard browser extension, users can verify if a website is a trustworthy source of health information. Visit the Newsweek VaxFacts website to learn more and to download the HealthGuard browser extension.
